Westfield Capital Management
MLTX icon

Westfield Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Westfield Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,259,376
Closed -$59.4M – 265
2025
Q2 		$59.4M Sell
1,259,376
-175,394
-12% -$7.14M 0.25% 123
2025
Q1 		$56.1M Buy
1,434,770
+123,151
+9% +$5.31M 0.27% 115
2024
Q4 		$71M Buy
1,311,619
+144,261
+12% +$7.37M 0.31% 100
2024
Q3 		$58.9M Buy
1,167,358
+49,733
+4% +$2.33M 0.27% 125
2024
Q2 		$49.1M Buy
1,117,625
+206,752
+23% +$8.76M 0.24% 136
2024
Q1 		$45.8M Buy
910,873
+298,823
+49% +$16.2M 0.24% 145
2023
Q4 		$37M Buy
612,050
+220,771
+56% +$11.4M 0.22% 161
2023
Q3 		$22.3M Sell
391,279
-18,840
-5% -$1.04M 0.15% 165
2023
Q2 		$20.9M Buy
+410,119
New +$11M 0.13% 170

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Westfield Capital Management's MLTX Position: Q3 2025 in Review

Westfield Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2025, closing a stake of 1,259,376 shares — an estimated $59.4M sold.

Westfield Capital Management first reported a position in MLTX in Q2 2023 and held it in 9 quarters. The position peaked at $71M in Q4 2024. 134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

  • Westfield Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Westfield Capital Management sold 1,259,376 MoonLake Immunotherapeutics shares in Q3 2025, an estimated $59.4M.
  • Westfield Capital Management first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 9 quarters.
  • Westfield Capital Management's MoonLake Immunotherapeutics position peaked at $71M in Q4 2024.
  • 134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on Westfield Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.